Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (ASX:PBT) covers the month of December 2017, with the report dated December 22, 2017. The filing serves as a Change of Director's Interest Notice under ASX Listing Rule 3.19A.2 and Section 205G of the Corporations Act. The registrant is a foreign private issuer based in Parkville, Victoria, Australia.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding director shareholdings and does not contain financial performance data.
Material Changes
The primary material change disclosed is a transaction involving the Executive Chairman, Mr. Geoffrey Kempler, on December 19, 2017:
- Options Acquired: Mr. Kempler acquired 5,000,000 options through the exercise of options under the employer share option plan.
- Options Lapsed: A prior holding of 4,000,000 options lapsed.
- Share Holdings: Direct share holdings remained at 30,000, and indirect share holdings remained at 17,981,000 (Total: 18,011,000 shares).
- Net Position: Following the transaction, Mr. Kempler holds a total of 5,000,000 options and 18,011,000 ordinary shares.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document references an Explanatory Memorandum from the 2017 Notice of Annual General Meeting regarding the consideration for the options but does not detail the content of that memorandum.
Investor Verification Checklist
- Verify the terms and exercise price of the 5,000,000 options granted to Mr. Kempler via the 2017 Annual General Meeting Explanatory Memorandum.
- Confirm the reason for the lapse of the 4,000,000 prior options held by Mr. Kempler.
- Review the company's latest financial reports (Form 20-F) for actual revenue, cash flow, and liquidity metrics, as they are absent from this filing.
- Check for any subsequent filings regarding the closed period status of the transaction, though this filing states no clearance was required.